Belgium Approves Illuccix, a PSMA PET Imaging Agent for Prostate Cancer
July 8, 2025
Telix Pharmaceuticals has announced that Illuccix, its PSMA PET imaging agent for prostate cancer,has received marketing authorization in Belgium. This approval supports Telix’s missionto expand
